Septal reduction therapy (myectomy, alcohol septal ablation)
Septal reduction therapy (SRT) is the term a 2022 systematic review uses for surgical septal myectomy and alcohol septal ablation, which it calls the two most common forms. The review says SRT is indicated in patients who are refractory to medical treatments and that alcohol septal ablation works by inducing an iatrogenic myocardial infarction. MeSH describes septal myectomy as an open heart surgery to treat hypertrophic cardiomyopathy. The US label of dehydrated alcohol injection (ABLYSINOL) states an indication to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy. The same review pools 20 studies and reports more ventricular arrhythmia events with alcohol septal ablation than with myectomy; these were cohorts, and the page does not say which procedure is better.
Also called Septal myectomy · Alcohol septal ablation · SRT
- Intervention
- In this atlas
Overview
Technical summary
MeSH descriptor D000099303 (Septal Myectomy) is a broad match: its scope note names only the surgery, so it is narrower than the page, which also covers alcohol septal ablation. Evidence in this atlas: PMC11270481 (Reviews in Cardiovascular Medicine, 2022; CC BY 4.0; introduction and abstract quoted) and the openFDA drug label record for dehydrated alcohol injection, set id 314b1dab-8f4f-49ae-a105-f974842818b8 (NDA207987, BPI Labs, effective 2026-01-05), read for its indication statement only. The openFDA brand name field reads Dehydrated Alcohol while the label text names ABLYSINOL. No dose, technique, outcome registry or guideline was read.
About this intervention
- Type
- Procedure
- Mechanism
- Surgical septal myectomy removes thickened heart muscle directly; alcohol septal ablation induces a controlled myocardial infarction of the septum, as the review and the label wording describe.
Classification codes
-
D000099303
Claims and evidence
Context Adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy, as the US label of dehydrated alcohol injection (ABLYSINOL) states
- Recipient
- Adult
- Population
- Adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy, as the indication statement words it. The statement gives no age bounds.
- Care setting
- Not stated beyond the indication statement
- Geography
- United States (FDA-approved labeling, NDA207987)
- Life stage
- Adults (the label's word); no age bounds given
- Follow-up
- Not applicable (regulatory statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Adults with symptomatic hypertrophic obstructive cardiomyopathy
- Not candidates for surgical myectomy
- Excluded
- None stated
The openFDA drug label record for dehydrated alcohol injection (ABLYSINOL, BPI Labs, NDA207987; label effective 5 January 2026) states its indication: to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy. The record's brand name field reads Dehydrated Alcohol, and the label text names ABLYSINOL.
- Certainty method
- Not assessed
- Limitations
- This claim covers one label (set id 314b1dab-8f4f-49ae-a105-f974842818b8). A search of openFDA labels for the word septal in the indications listed ten records, all for dehydrated alcohol with the same indication wording; the other nine were not read. Only the indication statement is recorded; no dosing, administration, warning or clinical study text is recorded on this page. An FDA approval is a decision about a drug, not a finding about how well it works. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (6)
-
Supports openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987)
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2026-01-05
- Source state
- Current
- Version fingerprint
a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). Only the indication statement is quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987)
- Locator
- results[0].openfda.brand_name[0]
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2026-01-05
- Source state
- Current
- Version fingerprint
a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). Only the indication statement is quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987)
- Locator
- results[0].openfda.manufacturer_name[0]
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2026-01-05
- Source state
- Current
- Version fingerprint
a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). Only the indication statement is quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987)
- Locator
- results[0].effective_time
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2026-01-05
- Source state
- Current
- Version fingerprint
a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). Only the indication statement is quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987)
- Locator
- results[0].indications_and_usage[0], fragment 1 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2026-01-05
- Source state
- Current
- Version fingerprint
a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). Only the indication statement is quoted. The raw record is committed in the atlas repository.
-
Supports openFDA drug label record: Dehydrated Alcohol injection, ABLYSINOL (BPI Labs, NDA207987)
- Locator
- results[0].indications_and_usage[0], fragment 2 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- 2026-01-05
- Source state
- Current
- Version fingerprint
a5f2fa27e5db427f5d499e1cf04130a269995c77360052e6b05382cd83716461- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (https://open.fda.gov/license/, fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only; byte-identical to the copy fetched 2026-11-08). Only the indication statement is quoted. The raw record is committed in the atlas repository.
Context People with obstructive hypertrophic cardiomyopathy, as a 2022 systematic review of septal reduction therapy describes them
- Recipient
- Recipient not specified
- Population
- Patients with hypertrophic obstructive cardiomyopathy (the review abbreviates it HOCM) who had septal myectomy or alcohol septal ablation in 20 pooled studies. The abstract describes the condition as medical refractory; the pooled studies' own inclusion criteria were not read.
- Care setting
- Not stated; the pooled studies' settings were not read
- Geography
- Not stated in the passages read
- Life stage
- Not stated in the passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- The abstract reports an early phase (during the procedure, during hospitalization or within 30 days after) and a late phase; no other follow-up period was read
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients with obstructive hypertrophic cardiomyopathy who had septal myectomy or alcohol septal ablation in the 20 pooled studies
- Excluded
- None stated
The same review pooled 20 studies with 8025 patients. Its abstract reports that ventricular tachycardia or ventricular fibrillation, including appropriate implantable cardioverter defibrillator intervention, was significantly more frequent in the alcohol septal ablation cohort than in the septal myectomy cohort (10% against 5%). It says the risks of sudden cardiac death were similar in the two procedure groups, but that a higher incidence of sudden cardiac arrest, which included sudden cardiac death and resuscitated sudden cardiac arrest, was observed in the alcohol septal ablation group.
Applies to Recipient not specified People with obstructive hypertrophic cardiomyopathy, as a 2022 systematic review of septal reduction therapy describes them
- Certainty method
- Not assessed
- Limitations
- The pooled studies are cohorts: the introduction says no randomized controlled study compares the two procedures, so the groups may differ in ways the pooling does not remove. The abstract is the authors' summary; the risk ratios, confidence intervals and study-level data were not reproduced or checked here. The review searched to October 2020. The review does not separate the effect of patient selection from the procedure. This is not advice on which procedure to choose.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (7)
-
- Locator
- Abstract, Results, sentence 1
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, Results, sentence 2, fragment 1 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, Results, sentence 2, fragment 2 of 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, Results, sentence 2, comparison
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, Results, sentence 5, fragment 1
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, Results, sentence 5, fragment 2
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Abstract, Conclusions, sentence 1
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
The introduction of a 2022 systematic review of ventricular arrhythmias after septal reduction therapy (SRT) says that SRT is indicated in patients who are refractory to medical treatments, and that surgical septal myectomy and alcohol septal ablation are the two most common forms. It says no randomized controlled study compares the two, and that alcohol septal ablation works by inducing an iatrogenic myocardial infarction, unlike the direct resection of the thickened muscle in myectomy.
Applies to Recipient not specified People with obstructive hypertrophic cardiomyopathy, as a 2022 systematic review of septal reduction therapy describes them
- Certainty method
- Not assessed
- Limitations
- Background statements written by the review's authors in its introduction, not the review's results. The review searched to October 2020 and was published in 2022; later evidence, guidelines and the effect of newer medicines were not read. The word indicated is the authors'; no guideline was read for this page.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- Introduction, paragraph 1, sentence 4
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Introduction, paragraph 1, sentence 5
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Introduction, paragraph 1, sentence 6
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
-
- Locator
- Introduction, paragraph 1, sentence 7
- How it applies
- Quoted at this locator.
- Retrieved
- Source effective date
- Not reported
- Source state
- Current
- Version fingerprint
c62a7310ac81dcfede099a12be2ee8d55a5bcf7bce414e257cd550b6f4104559- Reuse basis
- PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own <license> element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact The US label of dehydrated alcohol injection states an indication in obstructive hypertrophic cardiomyopathy: Hypertrophic cardiomyopathy
The openFDA drug label record for dehydrated alcohol injection (ABLYSINOL, BPI Labs, NDA207987; label effective 5 January 2026) states its indication: to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy. The record's brand name field reads Dehydrated Alcohol, and the label text names ABLYSINOL.Limitations. This claim covers one label (set id 314b1dab-8f4f-49ae-a105-f974842818b8). A search of openFDA labels for the word septal in the indications listed ten records, all for dehydrated alcohol with the same indication wording; the other nine were not read. Only the indication statement is recorded; no dosing, administration, warning or clinical study text is recorded on this page. An FDA approval is a decision about a drug, not a finding about how well it works. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
-
Claim, not a settled fact A 2022 systematic review describes septal reduction therapy in obstructive hypertrophic cardiomyopathy: Hypertrophic cardiomyopathy
Applies to Recipient not specified People with obstructive hypertrophic cardiomyopathy, as a 2022 systematic review of septal reduction therapy describes them
The introduction of a 2022 systematic review of ventricular arrhythmias after septal reduction therapy (SRT) says that SRT is indicated in patients who are refractory to medical treatments, and that surgical septal myectomy and alcohol septal ablation are the two most common forms. It says no randomized controlled study compares the two, and that alcohol septal ablation works by inducing an iatrogenic myocardial infarction, unlike the direct resection of the thickened muscle in myectomy.Limitations. Background statements written by the review's authors in its introduction, not the review's results. The review searched to October 2020 and was published in 2022; later evidence, guidelines and the effect of newer medicines were not read. The word indicated is the authors'; no guideline was read for this page.
-
Claim, not a settled fact The same review pools ventricular arrhythmia events after alcohol septal ablation and septal myectomy: Hypertrophic cardiomyopathy
Applies to Recipient not specified People with obstructive hypertrophic cardiomyopathy, as a 2022 systematic review of septal reduction therapy describes them
The same review pooled 20 studies with 8025 patients. Its abstract reports that ventricular tachycardia or ventricular fibrillation, including appropriate implantable cardioverter defibrillator intervention, was significantly more frequent in the alcohol septal ablation cohort than in the septal myectomy cohort (10% against 5%). It says the risks of sudden cardiac death were similar in the two procedure groups, but that a higher incidence of sudden cardiac arrest, which included sudden cardiac death and resuscitated sudden cardiac arrest, was observed in the alcohol septal ablation group.Limitations. The pooled studies are cohorts: the introduction says no randomized controlled study compares the two procedures, so the groups may differ in ways the pooling does not remove. The abstract is the authors' summary; the risk ratios, confidence intervals and study-level data were not reproduced or checked here. The review searched to October 2020. The review does not separate the effect of patient selection from the procedure. This is not advice on which procedure to choose.
Record details
- Record id
cardio:septal-reduction-therapy-myectomy-alcohol-septal-ablation- Content hash
1608e97414f27b4f3caf43d80a2aadec25ea8ad14316559459dcb7463aa79d74